查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924674

人类高免疫球蛋白市场按产品类型、给药途径、应用和最终用户划分－2026-2032年全球预测

Human Hyperimmune Globulins Market by Product Type, Route of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年人类高免疫球蛋白市场价值为9.5993亿美元，预计到2026年将成长至10.424亿美元，年复合成长率为9.52%，到2032年将达到18.1498亿美元。

关键市场统计数据
基准年 2025 9.5993亿美元
预计年份：2026年 10.424亿美元
预测年份 2032 1,814,980,000 美元
复合年增长率 (%) 9.52%

本文重点介绍高免疫球蛋白疗法，概述其临床作用、生产实际情况、监管考虑因素和策略准入意义。

人类高免疫球蛋白（HIG）是一种由混合人类血浆製成的特殊免疫球蛋白疗法，对特定病原体具有高效价。它可用作高危险暴露期间的预防性和标靶治疗药物，在感染疾病控制、输血医学和急诊护理的交叉领域中发挥着至关重要的作用。其临床适应症涵盖了从已知暴露后预防病原体传播到为其自体免疫不足的脆弱患者群体提供辅助性治疗，使其成为现代临床工具包中不可或缺的生物製药部分。

新兴的临床需求、製造创新和政策转变正在共同改变高免疫球蛋白产品的供应、需求和获取动态。

高免疫球蛋白领域正经历一系列变革，这些变革由临床、技术和政策因素共同驱动，重塑供需平衡。在临床上，为满足临床医师对更精准的暴露后预防方案和免疫力缺乏患者辅助性治疗的需求，标靶免疫球蛋白的应用范围正在不断扩大。同时，供体筛检和病原体特异性抗体定量方法的创新正在提高产品的一致性，使生产商能够更好地根据临床需求调整生产，同时降低效力和安全性方面的差异。

近期关税措施对血浆衍生免疫球蛋白疗法的筹资策略、合规负担和供应链韧性的影响

各国实施的海关政策和贸易措施会对血浆衍生疗法的供应、成本结构和筹资策略产生连锁反应。近期关税调整促使企业重新检视全球筹资策略，迫使生产者和经销商重新评估跨境物流、供应商多元化和库存缓衝。与关税归类和清关相关的合规负担也随之增加，推高了行政成本，迫使企业投入更多资源用于贸易合规、供应计画和合约保障。

详细的细分观点揭示了产品类型、临床应用、医疗环境、给药途径和分销管道如何驱动差异化需求和业务重点。

细分市场分析揭示了不同产品类型、适应症、临床环境、给药途径和分销管道之间的显着差异，这些差异共同指南商业化和临床导入策略。产品组合的考虑范围涵盖巨细胞病毒免疫球蛋白、 B型肝炎免疫球蛋白、狂犬病免疫球蛋白、破伤风免疫球蛋白和水痘-带状疱疹免疫球蛋白，每种产品都有不同的临床路径、供体抗体谱和生产产能需求。这些产品特有的特性会影响生产计画的优先排序，以及製造商如何分配高效价血浆以满足最迫切的临床需求。

影响全球市场采购优先事项、供应安全和监管协调的区域比较趋势和基础设施因素

区域趋势对筹资策略、监管沟通和生产力计画至关重要，因为不同地区的医疗基础设施、捐血者资源和报销环境各不相同。在美洲，成熟的医疗体系和完善的血浆采集网路为急诊和门诊提供了稳定的产品供应。然而，区域监管审查和物流方面的考量会影响前置作业时间和分销范围。该地区的医疗机构倾向于优先整合循证通讯协定，用于暴露后预防和标靶治疗，从而维持医院药房和专科诊所可预测的需求模式。

HyperImmune价值链中，血浆来源、产品品质和临床实施弹性均由策略性企业能力和伙伴关係模式决定。

主要商业企业和生产网络之间的差异体现在其对血浆来源、生产规模、品质保证措施以及整个供应链策略伙伴关係关係的控制。拥有整合血浆采集和分离能力的企业通常能够更灵活地应对突如其来的需求高峰，并确保不同批次产品抗体滴度的一致性。同时，专业生产商和合约分离商凭藉其灵活的生产能力和专业技术，发挥关键作用，使治疗申办方能够快速扩大生产规模或专注于特定的高免疫标靶。

为製造商和医疗保健提供者提供切实可行的策略措施，以加强供应链基础、协调临床应用并运作具有弹性的分销模式。

产业领导者应优先投资于能够增强供应韧性、加强临床应用协调以及简化监管和商业化流程的专案。加强国内血浆采集系统并扩大与信誉良好的血浆分离商的策略合作，将有助于降低跨境供应中断的风险，同时更好地管理抗原特异性捐赠者库。此外，投资先进的捐赠者筛检和抗体定量工具，将提高批次间一致性，并为临床优先使用稀有高效价血浆提供基础。这些技术投资必须与稳健的合约框架相匹配，以应对关税波动并确保在压力情境下也能有效运作。

我们的混合方法研究途径结合了关键相关人员访谈、监管审查、工作流程图绘製和情境分析，以建立可靠的策略指导。

本研究采用混合方法，整合了相关人员访谈、监管文件、供应链分析和同行评审的临床文献，以建构高免疫球蛋白生态系统的全貌。研究人员从临床医生、医院药剂师、生产专家和供应链管理人员收集了主要的定性信息，以了解临床实际情况、临床决策驱动因素和产品管理实践。这些发现与包括监管指南、生产标准和公开的生产流程资讯在内的二级资讯来源进行了交叉核对，以确保数据的一致性并识别已发表数据的不足之处。

临床相关性、供应链需求和策略重点的综合考量将决定高免疫疗法的可及性和营运永续性。

总之，在技术先进且策略敏感的供应链中，高免疫球蛋白仍是针对性预防和支持性临床治疗的重要选择。由于暴露事件和脆弱患者群体，临床需求突发且至关重要，而生产和分销动态要求持续关注捐赠者招募、产品一致性和物流。积极投资于供应链韧性、协同采购和循证临床路径的相关人员将更有能力确保患者及时获得治疗，并控製成本和营运风险。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 人类高免疫球蛋白市场（依产品类型划分）

  • 巨细胞病毒免疫球蛋白
  • B型肝炎免疫球蛋白
  • 狂犬病免疫球蛋白
  • 破伤风免疫球蛋白
  • 水痘-带状疱疹免疫球蛋白

9. 依给药途径分類的人高免疫球蛋白市场

  • 肌肉内注射
  • 静脉注射
  • 皮下注射

第十章 人类高免疫球蛋白市场（按应用划分）

  • 暴露后预防
    • 动物咬伤
    • 输血暴露
    • 针刺伤
  • 治疗用途

第十一章 人类高免疫球蛋白市场（以最终用户划分）

  • 门诊治疗中心
  • 诊所
  • 医院

12. 各地区人高免疫球蛋白市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 人类高免疫球蛋白市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国人高免疫球蛋白市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国人类高免疫球蛋白市场

第十六章：中国人类高免疫球蛋白市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ADMA Biologics, Inc.
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring LLC
  • Emergent BioSolutions Inc.
  • Fresenius Kabi AG
  • GC Biopharma Co., Ltd.
  • Grifols, SA
  • Hualan Biological Engineering, Inc.
  • Kamada Ltd.
  • Kedrion SpA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-7A380DA7C417

The Human Hyperimmune Globulins Market was valued at USD 959.93 million in 2025 and is projected to grow to USD 1,042.40 million in 2026, with a CAGR of 9.52%, reaching USD 1,814.98 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 959.93 million
Estimated Year [2026] USD 1,042.40 million
Forecast Year [2032] USD 1,814.98 million
CAGR (%) 9.52%

A focused orientation to hyperimmune globulin therapies outlining clinical roles, manufacturing realities, regulatory considerations, and strategic access implications

Human hyperimmune globulins represent a specialized class of immunoglobulin therapies derived from pooled human plasma with high titers against specific pathogens. Used both as prophylaxis in high-risk exposures and as targeted therapeutics, these products occupy a critical niche at the intersection of infectious disease management, transfusion medicine, and emergency care. Clinical indications span prevention of pathogen transmission after known exposures and adjunctive therapy for vulnerable patient populations who lack sufficient endogenous immunity, positioning these biologics as essential components of contemporary clinical toolkits.

Beyond clinical utility, the landscape for hyperimmune globulins is shaped by complex supply chains, donor recruitment dynamics, regulatory oversight, and evolving standards for plasma-derived product manufacturing. Recent advances in assay technologies and donor screening have improved specificity and safety, yet manufacturing remains resource intensive, requiring concentrated plasma inputs and validated fractionation processes. As a result, stakeholders from clinicians to procurement officers must weigh operational constraints, logistical timelines, and evolving clinical guidelines when integrating hyperimmune globulins into care pathways. This introduction frames the subsequent analysis by highlighting clinical roles, production realities, and the strategic considerations that influence adoption and access.

Emerging clinical imperatives, manufacturing innovations, and policy shifts that are jointly transforming supply, demand, and access dynamics for hyperimmune globulin products

The hyperimmune globulin landscape is undergoing a set of transformative shifts driven by clinical, technological, and policy forces that are reshaping supply-demand equilibria. Clinically, expanded use cases for targeted immunoglobulins are emerging as clinicians seek more precise post-exposure prophylaxis options and adjunctive therapies for immunocompromised patients. Concurrently, innovations in donor screening and pathogen-specific antibody quantification have improved product consistency, enabling manufacturers to better align production with clinical need while reducing variability in potency and safety profiles.

From a systems perspective, consolidation within plasma collection and fractionation networks, together with strategic partnerships between biopharma and specialty manufacturers, is altering how capacity and capability are allocated. Regulatory agencies are also updating guidance around pathogen testing and lot release criteria, which increases transparency but can lengthen time-to-market for new lots. At the same time, digital health tools and data analytics are enabling more responsive inventory management and demand forecasting for hospital pharmacies and clinics, smoothing distribution while exposing vulnerabilities when supply chain shocks occur. Taken together, these shifts are creating both opportunities for targeted expansion and new risks that require coordinated risk management and strategic investment.

How recent tariff measures are reshaping sourcing strategies, compliance burdens, and supply chain resilience for plasma-derived immunoglobulin therapies

Tariff policies and trade measures enacted at national levels can have cascading effects on the availability, cost structure, and sourcing strategies for plasma-derived therapies. Recent tariff adjustments have incentivized a re-examination of global sourcing strategies, prompting manufacturers and distributors to reassess cross-border logistics, supplier diversification, and inventory buffers. Compliance burdens associated with tariff classifications and customs procedures also increase administrative overhead, driving organizations to allocate additional resources to trade compliance, supply planning, and contractual protections.

Importantly, tariff-driven cost pressures often translate into strategic shifts rather than immediate clinical changes. Manufacturers may respond by optimizing regional production footprints, lengthening supply agreements with local plasma collection sites, or accelerating investments in domestic fractionation capacity to mitigate exposure to border costs. Healthcare providers and procurement teams may prioritize procurement strategies that favor multi-source agreements and longer lead-times to absorb variability. In summary, while tariffs introduce friction and incremental cost considerations, the more consequential impacts manifest through altered sourcing patterns, supply chain resilience strategies, and the reallocation of capital toward capacity localization and compliance infrastructure.

In-depth segmentation perspectives revealing how product types, clinical applications, care settings, administration routes, and distribution channels drive differentiated demand and operational priorities

Segment-level analysis reveals differentiated dynamics across product types, indications, care settings, administration routes, and distribution channels that jointly inform commercialization and clinical adoption strategies. Product mix considerations range from Cytomegalovirus Immunoglobulin to Hepatitis B Immunoglobulin, Rabies Immunoglobulin, Tetanus Immunoglobulin, and Varicella Zoster Immunoglobulin, each governed by distinct clinical pathways, donor antibody profiles, and manufacturing throughput demands. These product-specific characteristics affect prioritization in production schedules and influence how manufacturers allocate high-titer plasma to meet the most time-sensitive clinical needs.

Application-driven segmentation distinguishes post-exposure prophylaxis from therapeutic use, with post-exposure demands further differentiated by exposure type such as animal bite, blood transfusion exposure, and needlestick injury. These clinical scenarios produce episodic but urgent demand patterns that require rapid distribution and robust inventory planning. End users span ambulatory care centers, clinics, and hospitals, each with unique procurement cycles, reimbursement frameworks, and cold-chain logistics. Route of administration considerations, including intramuscular, intravenous, and subcutaneous delivery, have implications for product formulation, nursing workflows, and outpatient versus inpatient use. Distribution channel dynamics encompass hospital pharmacy, online pharmacy, and retail pharmacy pathways, each presenting trade-offs in terms of immediacy of access, inventory holding models, and regulatory compliance. Integrating these segmentation lenses enables stakeholders to identify highest-impact interventions across clinical, operational, and commercial dimensions.

Comparative regional dynamics and infrastructure considerations that influence procurement priorities, supply security, and regulatory alignment across global markets

Regional dynamics are central to procurement strategies, regulatory interactions, and capacity planning as geographic markets exhibit distinct healthcare infrastructures, donor base availability, and reimbursement environments. In the Americas, mature healthcare systems and established plasma collection networks provide a foundation for steady product flow to both acute and outpatient settings, yet regional regulatory reviews and logistics considerations influence lead times and distribution footprints. Healthcare institutions in this region tend to emphasize integration of evidence-based protocols for post-exposure prophylaxis and targeted therapeutic use, supporting predictable demand patterns in hospital pharmacies and specialized clinics.

Europe, Middle East & Africa present a heterogeneous picture where regulatory harmonization efforts coexist with significant variance in plasma collection capacity and reimbursement frameworks. Certain subregions prioritize local manufacturing incentives and supply security policies, which affect how manufacturers approach regional investments and partnership models. Meanwhile, Asia-Pacific markets are characterized by rapidly evolving infrastructure, growing demand in urban referral centers, and active investment in domestic plasma fractionation capabilities. Across these regions, stakeholders balance priorities between supply security, cost containment, and clinical access, adopting region-specific strategies for donor engagement, cold-chain logistics, and regulatory alignment to ensure continuity of care.

Strategic company capabilities and partnership models that determine agility in plasma sourcing, production quality, and clinical adoption across the hyperimmune value chain

Key commercial players and manufacturing networks are differentiated by their control over plasma sourcing, manufacturing scale, quality assurance practices, and strategic partnerships across the supply chain. Organizations that maintain integrated plasma collection and fractionation capabilities typically have greater agility in responding to episodic surges in demand and in ensuring consistent antibody titers across product lots. Conversely, specialist manufacturers and contract fractionators play an important role by offering flexible capacity and niche expertise, enabling therapeutic sponsors to scale rapidly or to focus on particular hyperimmune targets.

Collaboration between clinical communities and manufacturers is increasingly important for product stewardship, lot traceability, and post-market surveillance. Firms that invest in transparent quality metrics and that foster strong relationships with hospital pharmacies and clinician advisory groups can reduce friction in adoption and create preferred-supplier dynamics. Additionally, partnerships that extend into diagnostics and donor screening technologies enhance the ability to produce higher-titer, pathogen-specific immunoglobulins. Ultimately, competitive advantage accrues to organizations that combine reliable plasma access, rigorous manufacturing controls, and proactive engagement with healthcare stakeholders to align supply with clinical needs.

Practical strategic moves for manufacturers and healthcare providers to fortify supply, align clinical use, and operationalize resilient distribution models

Industry leaders should prioritize investments that increase supply resilience, enhance clinical alignment, and streamline regulatory and commercial pathways. Strengthening domestic plasma collection and expanding strategic partnerships with trusted fractionators will reduce exposure to cross-border disruptions while enabling better control over antigen-specific donor pools. At the same time, investing in advanced donor screening and antibody quantification tools will improve lot consistency and inform clinical prioritization for scarce high-titer material. These technical investments should be paired with robust contractual frameworks designed to protect against tariff variability and to ensure performance under stress scenarios.

On the demand side, proactive engagement with clinicians and pharmacy leaders to develop standardized protocols for post-exposure prophylaxis and therapeutic use will reduce variability in ordering patterns and support predictable consumption. Establishing joint forecasting and inventory sharing arrangements between hospitals, ambulatory centers, and clinics can smooth episodic demand, while tailored distribution agreements with hospital pharmacies, online pharmacy platforms, and retail pharmacy networks will expand access pathways. Finally, aligning value propositions with payers and regulatory stakeholders through evidence generation and health economic analyses will facilitate reimbursement clarity and support broader clinical adoption.

A mixed-methods research approach combining primary stakeholder interviews, regulatory review, operational mapping, and scenario analysis to underpin robust strategic guidance

This research synthesis draws upon a mixed-methods approach that integrates stakeholder interviews, regulatory documentation, supply chain analysis, and peer-reviewed clinical literature to build a holistic picture of the hyperimmune globulin ecosystem. Primary qualitative inputs were sought from clinicians, hospital pharmacists, manufacturing experts, and supply chain managers to capture operational realities, clinical decision drivers, and product stewardship practices. These insights were triangulated with secondary sources including regulatory guidance, manufacturing standards, and publicly reported production process information to ensure consistency and to expose gaps in public data.

Analytical techniques included process-mapping of plasma sourcing and fractionation workflows, scenario analysis for supply disruption and tariff impacts, and comparative regional assessment of regulatory and distribution frameworks. Emphasis was placed on validating assumptions through cross-validation of interview insights and documented policy positions. Where possible, methodological limitations and data gaps were identified so that readers can understand the confidence bounds around operational and strategic recommendations. The approach balances qualitative depth with systems-level analysis to produce actionable intelligence for clinicians, manufacturers, and procurement leaders.

Synthesis of clinical importance, supply chain imperatives, and strategic priorities that jointly determine access and operational sustainability for hyperimmune therapies

In conclusion, hyperimmune globulins remain a critical therapeutic option for targeted prophylaxis and adjunctive clinical care, situated within a supply chain that is both technically demanding and strategically sensitive. Clinical demand is episodic yet essential, driven by exposure events and vulnerable patient cohorts, while manufacturing and distribution dynamics require sustained attention to donor recruitment, product consistency, and logistics. Stakeholders that proactively invest in supply resilience, collaborative procurement, and evidence-based clinical pathways will be better positioned to ensure timely access for patients and to manage cost and operational risks.

Looking forward, the interplay of manufacturing innovation, regulatory evolution, and regional capacity expansion will continue to define access and availability. Organizations that align clinical education, supplier partnerships, and strategic investments in domestic capacity will realize the most durable benefits. The concluding message is clear: pragmatic, coordinated action across the value chain is essential to translate the therapeutic promise of hyperimmune globulins into reliable clinical outcomes and sustainable operational models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Hyperimmune Globulins Market, by Product Type

  • 8.1. Cytomegalovirus Immunoglobulin
  • 8.2. Hepatitis B Immunoglobulin
  • 8.3. Rabies Immunoglobulin
  • 8.4. Tetanus Immunoglobulin
  • 8.5. Varicella Zoster Immunoglobulin

9. Human Hyperimmune Globulins Market, by Route of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. Human Hyperimmune Globulins Market, by Application

  • 10.1. Post-Exposure Prophylaxis
    • 10.1.1. Animal Bite
    • 10.1.2. Blood Transfusion Exposure
    • 10.1.3. Needlestick Injury
  • 10.2. Therapeutic Use

11. Human Hyperimmune Globulins Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Human Hyperimmune Globulins Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Hyperimmune Globulins Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Hyperimmune Globulins Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Hyperimmune Globulins Market

16. China Human Hyperimmune Globulins Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ADMA Biologics, Inc.
  • 17.6. Bayer AG
  • 17.7. Bio Products Laboratory Ltd.
  • 17.8. Biotest AG
  • 17.9. China Biologic Products Holdings, Inc.
  • 17.10. CSL Behring LLC
  • 17.11. Emergent BioSolutions Inc.
  • 17.12. Fresenius Kabi AG
  • 17.13. GC Biopharma Co., Ltd.
  • 17.14. Grifols, S.A.
  • 17.15. Hualan Biological Engineering, Inc.
  • 17.16. Kamada Ltd.
  • 17.17. Kedrion S.p.A.
  • 17.18. Novartis AG
  • 17.19. Octapharma AG
  • 17.20. Pfizer Inc.
  • 17.21. Sanofi S.A.
  • 17.22. Shanghai RAAS Blood Products Co., Ltd.
  • 17.23. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 17.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CYTOMEGALOVIRUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HEPATITIS B IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY RABIES IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY TETANUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY VARICELLA ZOSTER IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY VARICELLA ZOSTER IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY VARICELLA ZOSTER IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ANIMAL BITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ANIMAL BITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ANIMAL BITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY BLOOD TRANSFUSION EXPOSURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY BLOOD TRANSFUSION EXPOSURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY BLOOD TRANSFUSION EXPOSURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY NEEDLESTICK INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY NEEDLESTICK INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY NEEDLESTICK INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY THERAPEUTIC USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY THERAPEUTIC USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 116. GCC HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 134. G7 HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 140. NATO HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA HUMAN HYPERIMMUNE GLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)